Add like
Add dislike
Add to saved papers

Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: Results from the Phase 2b CONTROL study.

BACKGROUND: Emollients and keratolytics are frequently used to manage symptoms of congenital ichthyosis (CI). Systemic retinoid treatment is complicated by teratogenicity and dose-limiting adverse effects.

AIM: This analysis from the randomised Phase 2b CONTROL study investigated the characteristics of participants who responded to treatment with TMB-001, a novel topical isotretinoin ointment formulation.

METHODS: Participants ≥9 years with genetically confirmed CI and ≥2 (out of 4) Visual Index for Ichthyosis Severity (VIIS) assessment areas with ≥3 scaling score were randomised 1:1:1 to TMB-001 0.05%:TMB-001 0.1%:vehicle twice daily for 12 weeks. Efficacy end points included the proportion of participants with ≥50% reduction vs baseline in VIIS-scaling (VIIS-50) and ≥2-grade reduction in Investigator Global Assessment (IGA)-scaling score vs baseline. Changes in body surface area (BSA) involvement, Dermatology Life Quality Index (DLQI) scores, and Itch-Numeric Rating Scale (I-NRS) scores were assessed.

RESULTS: Of the 33 participants (TMB-001 0.05% [n = 11], 0.1% [n = 10], and vehicle [n = 12]), median age was 29 years, and most were male (64%) and White (79%). Baseline demographics were generally similar among participants who did or did not achieve TMB-001 treatment success. Participants who had lower mean BSA involvement and higher DLQI and I-NRS scores at baseline were more likely to achieve VIIS-50. Similarly, higher baseline DLQI and I-NRS scores were associated with IGA response; BSA involvement was similar for IGA responders vs nonresponders.

CONCLUSIONS: Higher DLQI and I-NRS scores at baseline were associated with participants achieving treatment success by VIIS-50 and IGA response. Lower BSA involvement was associated with VIIS-50 success.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app